Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19

The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease.

Detalles Bibliográficos
Autores principales: Buxeraud, Jacques, Faure, Sébastien, Fougere, Édouard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Nouveautés
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304942/
https://www.ncbi.nlm.nih.gov/pubmed/35891982
http://dx.doi.org/10.1016/j.actpha.2022.05.002
_version_ 1784752205389103104
author Buxeraud, Jacques
Faure, Sébastien
Fougere, Édouard
author_facet Buxeraud, Jacques
Faure, Sébastien
Fougere, Édouard
author_sort Buxeraud, Jacques
collection PubMed
description The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease.
format Online
Article
Text
id pubmed-9304942
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-93049422022-07-22 Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19 Buxeraud, Jacques Faure, Sébastien Fougere, Édouard Actual Pharm Nouveautés The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease. Elsevier Masson SAS. 2022-06 2022-07-22 /pmc/articles/PMC9304942/ /pubmed/35891982 http://dx.doi.org/10.1016/j.actpha.2022.05.002 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Nouveautés
Buxeraud, Jacques
Faure, Sébastien
Fougere, Édouard
Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
title Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
title_full Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
title_fullStr Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
title_full_unstemmed Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
title_short Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
title_sort le nirmatrelvir-ritonavir (paxlovid®), un traitement contre la covid-19
topic Nouveautés
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304942/
https://www.ncbi.nlm.nih.gov/pubmed/35891982
http://dx.doi.org/10.1016/j.actpha.2022.05.002
work_keys_str_mv AT buxeraudjacques lenirmatrelvirritonavirpaxloviduntraitementcontrelacovid19
AT fauresebastien lenirmatrelvirritonavirpaxloviduntraitementcontrelacovid19
AT fougereedouard lenirmatrelvirritonavirpaxloviduntraitementcontrelacovid19

Ejemplares similares